Kaposi's sarcoma-derived cell line
Cancer Research/Cell Biology
Lonza Optimized Protocol
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols
or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our
to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T
J Exp Med (2006) 203(5): 1235-1247
©2016 Lonza. All rights reserved.